default author photo

Fridtjof Lund-Johansen

University of Oslo - Department of Immunology and Transfusion Medicine

P. B. 4950 Nydalen

0424 Oslo

Norway

SCHOLARLY PAPERS

6

DOWNLOADS

943

TOTAL CITATIONS

6

Scholarly Papers (6)

1.

Evaluation of Remdesivir and Hydroxychloroquine on Viral Clearance in COVID-19 Patients: Results from the NOR-Solidarity Randomised Trial

Number of pages: 33 Posted: 11 Feb 2021
University of Oslo - Division of Emergencies and Critical Care, University of Oslo - Department of Research Support for Clinical Trials, University of Oslo - Oslo University Hospital, University of Oslo - Division of Emergencies and Critical Care, University of Oslo - Department of Immunology and Transfusion Medicine, University of Oslo - Institute of Clinical Medicine, University of Oslo - Institute of Clinical Medicine, Vestre Viken Hospital Trust, Diakonhjemmet Hospital, Sørlandet Hospital, Innlandet Hospital, University Hospital North Norway, University of Stavanger - Stavanger University Hospital, University of Oslo - Institute of Clinical Medicine, Vestre Viken Hospital Trust, University of Oslo - Division of Emergencies and Critical Care, University of Oslo - Oslo University Hospital, District General Hospital of Førde - Section for Rheumatology, Haugesund Hospital, Vestre Viken Hospital Trust, Vestre Viken Hospital Trust, Møre og Romsdal Hospital Trust, Telemark Hospital Trust, Haraldsplass Deaconess Hospital, Sørlandet Hospital, Møre & Romsdal Hospital Trust - Molde Hospital - 8Department of Internal Medicine, Innlandet Hospital Trust, Nord-Trøndelag Hospital Trust, University of Oslo - Department of Immunology and Transfusion Medicine, University of Oslo - Institute of Clinical Medicine, University of Oslo - Department of Immunology and Transfusion Medicine, Trondheim University Hospital, Akershus University Hospital - Department of Infectious Diseases, Lovisenberg Diaconal Hospital - Department of Medicine, University of Oslo - Institute of Clinical Medicine, University of Bergen - Department of Clinical Science, Østfold Hospital Kalnes - Department of Infectious Diseases, University of Oslo - Oslo University Hospital, University of Oslo - Institute of Clinical Medicine, University of Oslo - Institute of Clinical Medicine, University of Oslo - Institute of Clinical Medicine, University of Oslo - Section for Clinical Immunology and Infectious Diseases and University of Oslo - Institute of Clinical Medicine
Downloads 330 (227,311)
Citation 5

Abstract:

Loading...

2.

Effects of Remdesivir in Hospitalized Patients with COVID-19: Systematic Review and Individual Patient Data Meta-Analysis of Randomized Clinical Trials

Number of pages: 32 Posted: 11 Oct 2022
Basel University - CLEAR Methods Center, University of Basel - University Hospital Basel, Hôpital Bichat, APHP, University of Oslo - Oslo University Hospital, University of Paris, Sorbonne University - Institut Pierre-Louis d'Epidémiologie et de Santé Publique, Hôpital Bichat, APHP, University of British Columbia (UBC), University of North Carolina (UNC) at Chapel Hill - National Institute of Health, Government of the People's Republic of China - Department of Pulmonary and Critical Care Medicine, Helsinki University Hospital, Hospices Civils de Lyon - Département des Maladies Infectieuses et Tropicales, Université Libre de Bruxelles (ULB), University of Claude Bernard Lyon 1, Hospices Civils de Lyon - Laboratoire de Virologie, University of Toronto, McGill University - Division of Experimental Medicine, University of Toronto - Sunnybrook Health Sciences Centre, University of Oslo - Oslo University Hospital, University of Oslo - Department of Immunology and Transfusion Medicine, University of Oslo - Oslo University Hospital, affiliation not provided to SSRN, China-Japan Friendship Hospital - Department of Pulmonary and Critical Care Medicine, University of North Carolina (UNC) at Chapel Hill - National Institute of Health, University of Basel - University Hospital Basel, University of Basel - University Hospital Basel, University of Basel - University Hospital Basel, University of Basel - University Hospital Basel, University of Basel - University Hospital Basel, University of Basel - Basel Institute for Clinical Epidemiology and Biostatistics, University of Basel - University Hospital Basel, Hôpital Bichat - Claude-Bernard - INSERM, IAME Infectious Diseases Department, Sorbonne University - Institut Pierre Louis d'Épidémiologie et de Santé Publique IPLESP, University of Oslo - Oslo University Hospital and University of Basel - University Hospital Basel
Downloads 190 (399,431)

Abstract:

Loading...

Remdesivir, COVID-19, systematic review, individual patient data meta analysis, randomized controlled trials, GS-5734

3.

Efficacy and Safety of Baricitinib for the Treatment of Hospitalized Adults with Severe or Critical COVID-19 (Bari-SolidAct): A Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Trial

Number of pages: 34 Posted: 03 Aug 2022
University of Oslo - Section for Clinical Immunology and Infectious Diseases, Universidad Autónoma de Madrid - Hospital Universitario La Paz. IdiPAZ, Sorbonne University - Institut Pierre-Louis d'Epidémiologie et de Santé Publique, University of Oslo - Institute of Clinical Medicine, University of Lille, affiliation not provided to SSRN, University of Verona, Hospital Universitario Virgen Macarena - Unidad Clínica de Enfermedades Infecciosas, affiliation not provided to SSRN, Université Libre de Bruxelles (ULB), Medical University of Innsbruck, Government of Portugal - Unidade Local de Saúde de São João, affiliation not provided to SSRN, affiliation not provided to SSRN, University of Oslo - Oslo University Hospital, University of Oslo - Oslo University Hospital, University of Oslo - Oslo University Hospital, Sorbonne University, University of Oslo - Division of Emergencies and Critical Care, University of Claude Bernard Lyon 1, affiliation not provided to SSRN, University of Pécs, National and Kapodistrian University of Athens, University Hospital Brno, University of Basel - University Hospital Basel, Hacettepe University, Technische Universität München (TUM), Hospices Civils de Lyon - Département des Maladies Infectieuses et Tropicales, Sorbonne University - Institut Pierre Louis d'Épidémiologie et de Santé Publique IPLESP, University of Oslo - Oslo University Hospital, Sorbonne University, University of Oslo - Oslo University Hospital, affiliation not provided to SSRN, Vestre Viken Hospital Trust, Groupe Hospitalier de la Région Mulhouse Sud-Alsace, University of Oslo - Institute of Clinical Medicine, University of Stavanger - Stavanger University Hospital, Hospital Universitario La Paz, Vestre Viken Hospital Trust, University Hospital North Norway, Hospices Civils de Lyon - Service de Médecine Intensive-Réanimation, Akershus University Hospital - Department of Infectious Diseases, Norwegian Institute of Public Health, Sorbonne University, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, University of Oslo - Department of Immunology and Transfusion Medicine, Hospices Civils de Lyon - Laboratoire de Virologie, University of Nantes - INSERM, University of Oslo - Oslo University Hospital, Norwegian Institute of Public Health, University of Verona - Infectious Diseases, Department of Diagnostic and Public Health, affiliation not provided to SSRN, University of Oslo - Department of Research Support for Clinical Trials and Sorbonne University - Institut Pierre Louis d'Épidémiologie et de Santé Publique IPLESP
Downloads 176 (428,796)

Abstract:

Loading...

COVID-19, immunomodulator, safety, baricitinib, JAK inhibitor

4.

T Cell Responses to Repeated SARS-CoV-2 Vaccination and Breakthrough Infections in Patients on TNF Inhibitor Treatment: A Prospective Cohort Study

Number of pages: 27 Posted: 05 Feb 2024
Norwegian Institute of Public Health, Akershus University Hospital, Diakonhjemmet Hospital, Norwegian Institute of Public Health, Norwegian Institute of Public Health, Norwegian Institute of Public Health, Diakonhjemmet Hospital, Norwegian Institute of Public - Department of Infectious Disease Surveillance and Environmental Health, Norwegian Institute of Public Health, Diakonhjemmet Hospital, Norwegian Institute of Public Health, University of Oslo - KG Jebsen Centre for B Cell Malignancies, University of Oslo - Akershus University Hospital, Diakonhjemmet Hospital, Diakonhjemmet Hospital, Diakonhjemmet Hospital, Akershus University Hospital, University of Oslo, University of Oslo - Institute of Clinical Medicine, University of Oslo - Institute of Clinical Medicine, Diakonhjemmet Hospital - Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), University of Oslo, University of Oslo - Department of Immunology and Transfusion Medicine, University of Oslo - KG Jebsen Centre for B Cell Malignancies, Diakonhjemmet Hospital, Diakonhjemmet Hospital, Akershus University Hospital and Norwegian Institute of Public Health - Department of Method Development and Analytics
Downloads 97 (704,534)

Abstract:

Loading...

TNF inhibitors, tumour necrosis factor inhibitor, SARS-CoV-2, vaccination, T cells, polyfunctionality, inflammatory bowel disease, arthritis

5.

Safety of Baricitinib in Vaccinated Patients with Severe and Critical COVID-19. Sub Study of the Randomised Bari-SolidAct Trial

Number of pages: 30 Posted: 19 Jul 2024
University of Oslo - Oslo University Hospital, University of Oslo - Oslo University Hospital, University of Oslo - Oslo University Hospital, Lyon Sud Hospital, University of Lille, Hospital Universitario La Paz, Hospices Civils de Lyon, University of Claude Bernard Lyon 1, Sorbonne University - Institut Pierre-Louis d'Epidémiologie et de Santé Publique, University of Oslo - Oslo University Hospital, University of Oslo - Oslo University Hospital, University of Nantes - INSERM, University of Nantes - INSERM, University of Oslo - KG Jebsen Centre for B Cell Malignancies, University of Oslo - Oslo University Hospital, University of Oslo - Oslo University Hospital, University of Oslo - Oslo University Hospital, University of Oslo - Department of Immunology and Transfusion Medicine, University of Oslo - Institute of Clinical Medicine, Groupe Hospitalier de la Région Mulhouse Sud-Alsace, Groupe Hospitalier de la Région Mulhouse Sud-Alsace, Amiens Picardie University Hospital - Intensive Care Unit, Hospices Civils de Lyon - Service de Médecine Intensive-Réanimation, University of Bordeaux - CHU de Bordeaux, University of Bordeaux - CHU de Bordeaux, Assistance Publique-Hôpitaux de Paris - Service de Réanimation Médicale Et Infectieuse (MI2), Université Paris Cité, Louis Mourier Hospital, Dijon University Hospital - Clinical Epidemiology Unit, University of Nantes - INSERM, Centro Hospitalar Universitário de Lisboa Central, University of Oslo, Vestre Viken Hospital Trust, Vestre Viken Hospital Trust, University of Stavanger - Stavanger University Hospital, University of Oslo - Oslo University Hospital, University Hospital North Norway, Østfold Hospital Kalnes - Department of Infectious Diseases, University of Oslo - Oslo University Hospital, University of Oslo - Institute of Clinical Medicine, University of Oslo - Oslo University Hospital, University of Oslo - Oslo University Hospital, Sorbonne University - Institut Pierre Louis d'Épidémiologie et de Santé Publique IPLESP, Hôpital Bichat - Claude-Bernard - INSERM, IAME Infectious Diseases Department, University of Oslo - Oslo University Hospital, University of Oslo - Division of Emergencies and Critical Care, University of Oslo - Oslo University Hospital, University of Oslo - Institute of Clinical Medicine and University of Oslo - Section for Clinical Immunology and Infectious Diseases
Downloads 94 (720,278)

Abstract:

Loading...

COVID-19, vaccination, baricitinib, JAK inhibitors, immunomodulation, elderly

6.

Preexisting Cross-Reactive T Cells are Boosted and Comprise Significant Immunity in COVID-19 Recovered Patients

Number of pages: 55 Posted: 24 Feb 2021
University of Oslo - KG Jebsen Centre for B Cell Malignancies, University of Oslo - KG Jebsen Centre for B Cell Malignancies, University of Oslo - KG Jebsen Centre for B Cell Malignancies, University of Oslo - Institute of Clinical Medicine, Vestre Viken Hospital Trust, Oslo University Hospital - Department of Immunology, University of Oslo - Department of Immunology and Transfusion Medicine, Oslo University Hospital - Department of Microbiology, Norwegian Institute of Public - Department of Infectious Disease Surveillance and Environmental Health, Norwegian Institute of Public Health - Department of Method Development and Analytics, University of Oslo - Institute of Clinical Medicine and University of Oslo - KG Jebsen Centre for B Cell Malignancies
Downloads 56 (1,000,027)
Citation 1

Abstract:

Loading...